Prostate Specific Antigen, Total - Medicare Screening
Also known as: PSA SCN
Use
This test is used as a preferred initial screening test for prostate cancer in conjunction with a digital rectal exam. It is also utilized to monitor patients for recurrence of cancer. The Roche PSA method aids in the detection of prostate cancer when used with a digital rectal exam in individuals with a prostate age 50 years and older. It helps in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can suggest the presence of prostate cancer until biopsy is performed. However, PSA levels can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate.
Special Instructions
This test should be ordered for screening purposes for Medicare patients only. Results obtained with different test methods or kits cannot be used interchangeably.
Limitations
The Roche PSA electrochemiluminescent immunoassay is used and results obtained with different test methods or kits cannot be used interchangeably. PSA concentrations can be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy individuals or individuals with nonprostatic carcinoma. Elevated PSA levels can only suggest the presence of prostate cancer until a biopsy is performed.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 83112-3
Result Turnaround Time
null-1 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Transport 1 mL serum or plasma.
Causes for Rejection
Hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 5 days |
| Frozen | 6 months |